Burning Rock reported Q4 2025 revenue of RMB126.3 million, up 10% in gross profit to RMB98.57 million. Q4 net loss narrowed to RMB15.4 million from a year earlier, while operating expenses fell 36% to RMB110.6 million due to budget control measures including headcount reduction. In Q4, central laboratory revenue rose 12% to RMB44 million on higher CanCatch test volumes, while in-hospital revenue increased 17% to RMB51 million driven by higher sales volume from existing hospitals and new contracted partner hospitals. For FY 2025, revenue increased 5% to RMB539.57 million and net loss narrowed to RMB55.35 million. FY 2025 pharma research and development services revenue rose 35% to RMB155.5 million on increased development and testing services for pharma customers, while cash, cash equivalents and restricted cash totaled RMB481.09 million as of Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120708PRIMZONEFULLFEED9670857) on March 12, 2026, and is solely responsible for the information contained therein.